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AKTIVITI ANTIDIABETIK CUKA NYPA FRUTICANS WURMB. 
 
ABSTRAK 
Cuka Nypa fruticans Wurmb., secara tempatan dikenali sebagai cuka nipah 
(NPV) di Malaysia, dipercayai mempunyai ciri-ciri antidiabetik yang tinggi. Kajian ini 
dijalankan untuk mengkaji aktiviti antidiabetik dan mekanisma-mekanisma tindakan 
yang mungkin bagi NPV. Pengekstrakan cecair-cecair diguna untuk memisahkan 
komponen-komponen NPV berdasarkan kekutuban kepada ekstrak etil asetat (EE) dan 
ekstrak akues (AE). AE, seterusnya difraksinasi menggunakan kaedah asid hidrolisis 
kepada dua subfraksi: SFI dan SFII. NPV, EE, AE, SFI dan SFII diberikan kepada tikus 
non diabetik dan/atau tikus diabetik aruhan streptozotosin (STZ) menggunakan gavaj 
oral. Aras glukosa darah (BGLs), aras insulin dan perubahan histologi pada hati dan 
pankreas direkod.  Kesan in vitro AE terhadap aktiviti enzim α–glukosidase and α–
amilase, dan juga penyerapan/ pengambilan glukosa pada kantung jejuna tikus terisolasi 
dan otot rangka; turut dikaji. Tiada kesan hipoglisemik akut dilihat pada tikus non 
diabetik setelah diberikan NPV, EE dan AE pada dos 1 g/kg. Walaubagaimanapun, 
NPV dan AE merencat kenaikan BGLs secara signifikan dalam tikus terbeban glukosa 
pada minit ke 90. Namun, pemberian NPV, EE dan AE kepada tikus diabetik aruhan 
STZ menunjukkan tiada kesan antihiperglisemik direkodkan dalam pemerhatian selama 
7 jam. Rawatan sub-kronik oral selama 12 hari pada tikus diabetik membuktikan 
bahawa AE mempunyai aktiviti antihiperglisemik yang paling tinggi, secara 
keseluruhannya. Penilaian imunohistokimia pada tisu pankreas menunjukkan,walaupun 
tiada kesan regenerasi, AE merangsang penghasilan insulin daripada sel-sel β yang 
masih berfungsi. AE juga memperbaiki struktur histologi pada hati. AE menurunkan 
 xv 
 
BGLs, memperbaiki aras insulin serum dan menormalkan profil lipid tikus diabetik 
tanpa menyebabkan ulser gastrik atau pertambahan/ penurunan berat badan. Justeru itu, 
AE dipilih bagi kajian mekanisma tindakan yang lebih mendalam. Ujian secara in vitro 
menunjukkan AE merencat penyerapan glukosa pada jejunum. Penemuan ini disokong 
dengan ujian toleransi karbohidrat oral apabila perencatan yang signifikan dilihat 
terhadap kenaikan aras glukosa darah. AE juga tidak merencat aktiviti α–glukosidase 
and α–amilase. Seterusnya, AE menunjukkan kesan rangsangan yang signifikan 
terhadap pengambilan glukosa oleh otot rangka dan kesan perlindungan terhadap hepar. 
Analisis fitokimia menunjukkan AE mempunyai jumlah fenolik dan kandungan 
antioksidan yang secara relatifnya adalah rendah berbanding dengan ekstrak atau fraksi 
yang lain. Analisis HPLC mencadangkan bahawa aktiviti antihiperglisemik AE adalah 
disebabkan oleh kehadiran asid asetik dalam kuantiti yang tinggi. Walaubagaimanapun, 
kajian yang lebih mendalam perlu dijalankan bagi mengenalpasti kandungan komponen 
bioaktif yang hadir dalam NPV.  
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ANTIDIABETIC ACTIVITY OF NYPA FRUTICANS WURMB. VINEGAR 
 
ABSTRACT 
Nypa fruticans Wurmb. vinegar, locally known as nipa palm vinegar (NPV) in 
Malaysia, is believed to have remarkable antidiabetic properties. This study sought to 
elucidate the vinegar’s antidiabetic activity and possible mechanisms of action. Liquid–
liquid extraction was used to separate the compounds in NPV based on polarity into an 
ethyl acetate extract (EE) and an aqueous extract (AE). AE was further fractionated 
using acid hydrolysis into two sub-fractions: SFI and SFII. NPV, EE, AE, SFI and SFII 
were administered using oral gavage in non diabetic and/or diabetic rats induced by 
streptozotocin (STZ). Blood glucose levels (BGLs), insulin levels, and liver and 
pancreatic histological changes were recorded. In vitro effects of AE on α–glucosidase 
and α–amylase activities, as well as on glucose absorption/ uptake in isolated rat jejunal 
sacs/ skeletal muscles; were observed. No acute hypoglycemic effect was shown in non 
diabetic rats upon administering up to 1 g/kg of NPV, EE or AE. Nevertheless, NPV 
and AE significantly ameliorated high BGLs at 90 minutes in glucose-loaded rats. Yet, 
administration of NPV, EE and AE to STZ-induced diabetic rats showed no 
antihyperglycemic effects for up to 7 h. Sub-chronic 12-day oral treatment in diabetic 
rats revealed that AE had a superior antihyperglycemic activity overall. 
Immunohistochemical assessment of the animals’ pancreatic tissues showed that, albeit 
having no regenerative effect, AE stimulated the secretion of insulin from viable β–
cells. It also precipitated structural recovery in the liver. It lowered BGLs, improved 
serum insulin levels and normalized the lipid profile of the animals, with no signs of 
gastric ulcer or abnormal body weight gain/loss. Consequently, AE was chosen for 
 xvii 
 
elaborate antidiabetic mechanism studies. In vitro tests showed that AE inhibited the 
absorption of glucose from jejunum. This finding was further supported by significant 
suppression in the rise of blood glucose level seen in oral carbohydrate tolerance tests. 
AE also did not inhibit the activities of α-glucosidase and α-amylase. Furthermore, AE 
was shown to significantly enhance the uptake of glucose by skeletal muscles and exert 
hepatoprotective effect. Phytochemical analysis indicated that AE had relatively low 
total phenolic and antioxidant contents compared to the other tested extracts/fractions. 
HPLC analysis rather suggested that the antihyperglycemic activity was due to the 
presence of a major quantity of acetic acid. However, further investigation is needed to 
fully elucidate the nature of the bioactive compounds present in NPV.  
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CHAPTER ONE: INTRODUCTION 
 
1.1  Background 
Diabetes mellitus (DM) is a heterogenous metabolic disorder characterized by persistent 
hyperglycemia in fasting and/or postprandial states with abnormalities in the 
metabolism of carbohydrate, protein and fat due to the impairment of insulin secretion 
by pancreatic beta cells, insulin action at the targeted tissues or both (ADA, 2008; 
Adam, Ismail, Khamis, Mokhtar, & Hamid, 2011). Symptoms of marked hyperglycemia 
include polydipsia, polyuria, weight loss, extreme tiredness and blurred vision. 
Susceptibility to certain infections and impaired growth may also occur with chronic 
hyperglycemia. The chronic hyperglycemia will cause long-term damage and failure of 
specific organs, especially the kidneys, eyes, heart, nerves and blood vessels due to the 
complications of the macrovascular (peripheral vascular disease, ischemic heart disease 
and cerebrovascular disease) and microvascular (nephropathy, retinopathy and 
neuropathy) (Cade, 2008). Insulin therapy, oral antidiabetic drugs and lifestyle changes, 
for example exercise, weight control and diet management, are recommended for 
controlling and treating diabetes (Hui, Tang, & Go, 2009). 
The global prevalence of DM is increasing at an alarming rate and has reached 
epidemic proportions. According to the International Diabetes Federation, 
approximately 382 million people, or 8.3% of adults worldwide living with diabetes in 
2013 and the number has been forecasted to increase to 592 million by 2035. About 
80% of the total diabetes cases reported in the low- and middle- income countries. 
Among the top 10 countries of the largest numbers of people with diabetes (20 to 79 
years old), five are in the Asia region; China, India, Indonesia, Egypt and Japan. 
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According to the National Health and Morbidity Survey (NHMS III), Malaysia in 
particular has recorded a 31% increase in DM case among adults in the period of just 5 
years, from 11.6% in 2006 to 15.2% in 2011 (Amal, Paramesarvathy, Tee, Gurpreet, & 
Karuthan, 2011). Furthermore, based on the latest result of NHMS and National 
Diabetes Registry (NDR) database, the prevalence of diabetes among adults age 18 
years and above is predicted to rise to 21.6% by 2020. 
Functional foods have captivated considerable interest as potential alternative 
therapies for the treatment of diabetes mellitus and its complications. Incorporating 
functional foods in the dietary regimen of diabetic patients proved to favourably 
influence blood glucose level. According to Functional Food Center USA, functional 
foods are defined as natural or processed foods that contain known or unknown 
biologically – active compounds; which, in defined, effect non – toxic amounts, provide 
a clinically proven and documented health benefit for the prevention, management, or 
treatment of chronic disease (Martirosyan & Singh, 2015). Besides of the minimal side 
effect in clinical practices and relatively low cost, the growing interest in functional 
foods is also because of the increase scientific studies regarding their effectiveness. 
Some of the extensively studied functional foods for the treatment of diabetes mellitus 
are Allium sativum L., Momordica charantia L., Punica granatum, Curcuma longa L., 
and Mangifera indica (Perera & Li, 2012). 
Vinegar is one of the widely consumed functional foods worldwide. The 
consumption of vinegar with meals was used as a home remedy for diabetes before the 
advent of pharmacologic glucose-lowering drugs (O' Keefe, Gheewala, & O' Keefe, 
2008). Many recent scientific reports in both humans and animals have shown that 
vinegar consumption could reduce the postprandial blood glucose concentrations 
(Brighenti et al., 1995; Gu et al., 2012; Östman, Granfeldt, Persson, & Björck, 
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2005). The antiglycemic property of vinegar was also demonstrated to extend to 
individuals with type 1 diabetes mellitus and type 2 diabetes mellitus. Among the 
previously studied vinegars are apple cider vinegar (Abu-Zaiton, 2011; Hlebowicz, 
Darwiche, Björgell, & Almér, 2007; Johnston, 2009; Kondo, Kishi, Fushimi, Ugajin, & 
Kaga, 2009), grape vinegar (Kahraman et al., 2011), balsamic vinegar (Seok et al., 
2012), wine vinegar (Liatis et al., 2010), and white rice vinegar (Gu et al., 2012). 
Although different types of vinegars have been studied for decades for their 
medicinal properties, there is no scientific investigation on the effects of nipa palm 
vinegar (NPV) towards diabetes has been conducted. NPV has been widely consumed 
by the local community as part of the diet and also as a folk medicine to treat diabetes, 
high blood pressure, rheumatoid arthritis and insomnia (O. Salmiah, personal 
communication, October 27, 2014). It is made from a local alcoholic beverage called 
‘nira’ which is produced from the flower cluster (inflorescence) of nipa palm (Nypa 
fruticans). Therefore, this study is designed to determine the effects of NPV prepared 
from Malaysian nipa palm plant on biochemical parameters of non diabetic and STZ-
induced diabetic rat models. Mechanisms underlying the observed antidiabetic activities 
of NPV are further studied in an attempt to understand the possible role of NPV at the 
pancreatic, intestinal and peripheral levels.  
 
1.2  Definition and classification of diabetes mellitus 
The word ‘diabetes’ comes from a Greek word which means ‘to pass through’, was first 
used by Aretaeous of Capadocia in the 2nd century A.D. to refer to a condition of 
excessive production of urine or polyuria (Alexiou & Demopoulos, 2010). The adjective 
‘mellitus’ is a Latin word that means ‘sweet like honey’ which refers to the high level of 
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sugar found in the urine (Merriam-Webmaster, 2008). In the early days, Greek 
physicians prescribed exercise, starvation diet, wine, and overfeeding to compensate 
fluid loss as ways to treat diabetes. In 600 B.C., well known ayurvedic physicians, 
Charaka and Susruta differentiated two types of diabetes, even though most of the 
described symptoms probably relate to currently used term of type 1 DM. Later, in the 
18th and 19th centuries, another variety of DM which is less clinically symptomatic, 
characterized by glucosuria, commonly related with overweight, and often discovered in 
later life, was noted. This type is today recognized as type 2 DM. It has become 
understandable subsequently that the term DM covers a wide spectrum of disease, from 
acute and sometimes explosive onset to asymptomatic people whose disease is detected 
by screening (Sarmah & Sharma, 2014). 
Nowadays, the American Diabetes Association has classified diabetes mellitus 
into four etiopathogenetic categories: type 1 diabetes, type 2 diabetes, gestational 
diabetes and diabetes due to multiple other specific causes, for example genetic defects, 
drug therapy, infection, etc (ADA, 2008). Type 1 diabetes mellitus, formerly known as 
juvenile diabetes or insulin-dependent diabetes, is characterized by an absolute 
deficiency of insulin secretion due to the progressive destruction of β-cells (Inzucchi & 
Sherwin, 2011). Insulin is a hormone crucially needed in the metabolism of 
carbohydrate, protein and fat (Figure 1.1). Loss of β-cells function is resulted from 
cellular-mediated autoimmune destruction of the pancreactic β-cells in which the body 
immune system is activated to destroy its own β-cells (Wang et al., 2013). 
Hyperglycemia condition happens when 80-90% of pancreatic β-cells have been 
destroyed. While this type commonly occurs in childhood and early adulthood, it can 
develop at any age. Patients with type 1 diabetes depend solely on the exogenous source  
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Figure  1.1: Diagram of the metabolic action of insulin on liver, adipocyte, and muscle 
cells. Green arrows represent the direction of processes enhanced by insulin whereas red 
arrows illustrate the direction of processes in the absence of insulin. Black arrows 
indicate non-insulin dependent processes. The lipoprotein lipase is located in the 
membranes of adipocyte capillaries (Adopted from Course D: Diabetes Lecture Notes 
by Dr Afia Ali In e-Learning Pages, Retrieved October 25, 2016, from 
http://elearn.pharmacy.ac.uk/diabetes/diabetes_07.htm. Copyright 2015 by Jason 
Cooper).  
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of insulin to control hyperglycemia as close as normal (Chiang, Kirkman, Laffel, & 
Peters, 2014). Type 1 DM accounts for only 5-10% of all diabetes cases. 
Type 2 diabetes mellitus is the major form of diabetes, accounting for about 90–
95% of those with diabetes. It previously referred to as adult-onset diabetes or non–
insulin dependent diabetes. This form of diabetes is characterized by the presence of 
insulin resistance – a condition in which body does not respond properly to insulin, a 
relative lack of insulin secretion and increased hepatic glucose output (Matusda & De 
Fronzo, 1999). Majority of the type 2 DM patients exhibits abdominal obesity which 
itself is the main cause of insulin resistance. In addition, dyslipidemia, hypertension, 
and elevated inhibitor of plasminogen activator 1 level are often manifested in type 2 
DM. The risk of developing this type of diabetes increases when diabetogenic lifestyle – 
inadequate calories expenditure, lack of exercise and obesity, is associated with having 
susceptible genetic predisposition (Wells et al., 2008). For some patients, insulin 
resistance may be improved with weight reduction through diet and exercise. Others 
might also need oral hypoglycemic drugs to manage the blood glucose level.  
Gestational diabetes mellitus (GDM) is defined as glucose intolerance which is 
first diagnosed during the pregnancy. GDM is diagnosed in about 7% of all pregnancies. 
During pregnancy, the placenta and placental hormones develop an insulin insensitivity 
that becomes pronounced in the last trimester. Hence, it is recommendable to do risk 
assessment for GDM starting from the first prenatal visit. Clinical screening is 
important as management for GDM that will lower perinatal mortality and morbidity 
(ADA, 2010; Karagiannis, Bekiari, Manolopoulos, Paletas, & Tsapas, 2011). 
The fourth type of diabetes is diabetes due to multiple other specific causes, 
including genetic defects of β-cells function and insulin actions, endocrinopathies, 
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diseases of the exocrine pancreas, endocrinopathies, nonpancreatic diseases, drug 
therapy, infection and non-pancreatic diseases (ADA, 2010). 
 
1.3  Pathogenesis aspects of diabetes mellitus 
DM is a heterogeneous disorder involving distinct pathogenic mechanisms in which 
hyperglycemia is the main symptom. Regardless of the cause, DM is closely related 
with a hormonal deficiency, namely, insulin, in either total, partial, or relative defects 
when discussed in the context of coexisting insulin resistance. Insulin defect is the main 
contributor to the metabolic derangement of carbohydrate, protein, and fat in DM and 
hyperglycemia, on the hand, plays a key role in the diabetes complications (ADA, 
2012). 
 In type 1 DM, absolute insulin deficiency resulted mostly from the autoimmune 
– mediated destruction of β cells in the islet of Langerhans of pancreas. The 
pathogenesis of type 1 DM has been assumed to be an interaction between genetics and 
environment factors (for e.g. toxins, vaccines, diet, viruses, stress, and infectious 
agents). Patients with type 1 DM have strong genetic linkages with DQA, B genes and 
certain human leukocytes antigens (HLAs) such as DR3 and DR4. In a genetically 
susceptible individual, environmental factors stimulate an autoimmune process by 
activating macrophages and T lymphocytes to circulate autoantibodies against various β 
cell antigens that results in destruction of pancreatic β islet cells which leads to insulin 
deficiency and hyperglycemia (Pittas & Greenberg, 2003). Several antibodies that 
related to type 1 DM include islet cell antibody, insulin autoantibodies, insulin 
antibodies against islet tyrosine phosphatase, and antibodies directed against glutamic 
acid decarboxylase. These antibodies are usually considered as markers for detecting 
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type 1 DM, rather than mediator for β cell destruction (Pihoker, Gilliam, Hampe, & 
Lernmark, 2005).  
 Type 2 DM involves two primary pathogenic mechanisms which are, 1) 
impaired insulin secretion (Weyer, Bogardus, Mott, & Pratley, 1999) and 2) peripheral 
insulin resistance involving muscle, liver and adipose tissues (ADA, 2008; Ahrén & 
Pacini, 2005). Impaired insulin secretion occurred due to the progressive destruction in 
the pancreatic β cell function or β cells mass (Clark, Jones, de Koning, Hansen, & 
Matthews, 2001). Although the progressive destruction of β-cell does not happen 
rapidly, the decline in β-cell function is inevitable, progressive and central to the 
pathophysiology of type 2 DM (Tibaldi, 2008). 
 Insulin resistance happened when the body does not respond the secreted insulin 
effectively. Hence, glucose starts to accumulate in the blood circulation instead of being 
absorbed by the cells. The most common cause of insulin resistance is obesity (Bell & 
Polonsky, 2001) and the increasing prevalence of obesity is probably responsible for the 
increasing prevalence of T2DM globally. Insulin resistance occurs even in lean type 2 
diabetic patients. With insulin resistance, liver, muscle, and adipose tissues do not 
response adequately to the insulin action (Wilcox, 2005). In mild type 2 DM individual, 
basal hepatic glucose production is elevated by approximately 0.5 mg/kg per minute. It 
is estimated that a diabetic individual of 80 kg with mild fasting hyperglycemia 
produces an additional 35 g of hepatic glucose during the overnight sleep hours. The 
additional fasting hepatic glucose production is the cause of fasting hyperglycemia 
(Cersosimo, Triplitt, Mandarino, & DeFronzo, 2015). During the fed state, insulin is 
released into the portal vein and carried to the liver. In healthy individual, hepatic 
glucose production will be suppressed. Due to the insulin resistance in type 2 DM 
individual, liver continues to produce glucose. At this point, there are two sources of 
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glucose in the systemic circulation; one from the gastrointestinal tract and second, from 
the liver. As a result, marked hyperglycemia ensued (Wilcox, 2005). 
 Skeletal muscle is the primary site of glucose uptake in the postprandial state. 
Approximately 80% of glucose is taken up by peripheral tissues is disposed of in 
skeletal muscles under euglycemic hyperinsulinemic condition (Thiebaud et al., 1982). 
In healthy individual, the glucose uptake by leg muscle increases linearly with time, 
reaching a plateau of about 10 mg/kg leg weight per minute after 60 minutes, in 
response to the increment in plasma insulin concentration. However, for mild type 2 
DM individual, the ability of leg muscle to stimulate glucose uptake is decreased by 
50% due to the 40 minutes delay in the onset of insulin action (DeFronzo & Tripathy, 
2009).   
In the postprandial state, the intracellular glucose transport into adipocytes is 
insulin-dependent via glucose transporter (GLUT) 4; it is estimated that adipose tissue 
accounts for about 10% of whole body glucose uptake (Smith, 2002). Insulin stimulates 
glucose uptake, promotes lipogenesis while suppressing lipolysis, which causes free 
fatty acid flux into the blood circulation. Adipose tissue depots differ in their response 
to insulin (Giorgino, Laviola, & Eriksson, 2005). Adipocytes in the type 2 DM and 
insulin resistant individuals have reduced GLUT 4 translocation, impaired intracellular 
signalling via reduced insulin receptor substrate – 1 gene and protein expression, 
impaired insulin-stimulated  diphosphoinositide (PIP) – 3  kinase and protein kinase B 
(Shan, Chen, Zhu, Jiang, & Zhou, 2011). 
 As discussed above, with insulin resistance, muscle, liver, and adipocytes do not 
adequately respond to the insulin actions. Typically, β-cells compensate insulin 
resistance by secreting more insulin. Although insulin hypersecretion predisposes 
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patients to β-cell dysfunction, impaired glucose tolerance (IGT) and eventual type 2 DM 
(Rolla, 2004), many insulin-resistant patients do not develop diabetes as long as the islet 
β-cells continue to hypersecrete insulin (Boden & Shulman, 2002). However, when β – 
cells loss the ability to hypersecrete insulin, marks progression from IGT to the fasting 
hyperglycemia occurred, that further characterizes type 2 DM (Rolla, 2004). 
 
1.4  Complications of diabetes 
Diabetes is a metabolic disorder that is strongly associated with several microvascular 
and macrovascular complications, resulting in multiple tissues and organs dysfunction, 
especially the kidneys, eyes, heart, nerves and blood vessels (Cade, 2008). 
Microvascular complications refer to the long term complications of diabetes that affect 
small blood vessel such as capillaries, arterioles and venules whereas macrovascular 
complications involve large blood vessels such as arteries and veins (Zimmerman, 
2016). According to UKPDS, both vascular complications are responsible for 
approximately one third to one half of morbidity and mortality in diabetes patients 
(Turner, Cull, & Holman, 1996). The severity and duration of hyperglycemia play the 
main role in initiating diabetic vascular complications through several metabolic and 
structural derangements (Cade, 2008).  
Microvascular complications included diabetic retinopathy, neuropathy and 
nephropathy. Diabetic retinopathy (DR) is a microvascular complication that affects the 
peripheral retina, the macula, or both and is the main cause of visual impairment and 
blindness in diabetes patients (WHO, 2007). There are several histological changes that 
occur with DR which are loss of pericytes, formation of microaneurysm, thickening of 
capillary basement membranes and increased permeability of endothelial cells (Carlson 
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et al., 2003; Hammes, 2005). Development and progression of DR depend significantly 
on the severity and duration of hyperglycemia (Henricsson, Nilsson, Janzon, & Groop, 
1997). Under hyperglycemia condition, retina blood flow impairment, capillary 
blockage and increased inflammatory cell adhesion to retinal blood vessels occur which 
can result in hypoxia and damage to the retina (Kohner, Patel, & Rassam, 1995). The 
severity of DR varies from nonproliferative and preproliferative to more chronic 
proliferative, characterized by the abnormal growth of new vessels on the surface of 
retina that can lead to vitreous hemorrhage (Harding, 2003). White areas on the retina 
can be a sign of impending proliferative retinopathy. If proliferation continues, 
blindness can occur through vitreous hemorrhage and traction retinal detachment. With 
no treatment, visual loss may occur. Laser photocoagulation can often prevent 
proliferative retinopathy from progressing to blindness (Watkins, 2003). 
Diabetic neuropathy (DN) is defined by the American Diabetes Association as 
the existence of symptoms and/or signs of peripheral nerve failure in diabetes patients 
after the exclusion of other cause (ADA, 2012). Approximately half of the diabetic 
population have been affected by peripheral neuropathy (Dyck et al., 1993) and more 
than 80% of amputations that happen after foot injury are due to DN (Boulton, 1997). 
Peripheral neuropathy can be classified into several types depending on the number of 
affected nerves, their functions and locations. Mononeuropathy affects single peripheral 
nerve at a time. If multiple sensory and motor nerves in the peripheral nervous system 
are being affected simultaneously, it is known as polyneuropathy (Said, 2007). In 
addition, DN can also affect autonomic nerves and cause diabetic autonomic 
neuropathy, including cardiac autonomic neuropathy, gastrointestinal autonomic 
neuropathy, and genitourinary autonomic neuropathy (Duby, Campbell, Setter, & 
Rasmussen, 2004; Vinik, Maser, Mitchell, & Freeman, 2003). Even though the precise 
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nature of the nerves injury due to hyperglycemia is yet uncertain, it is likely associated 
with oxidative stress, accumulation of polyol and injury from advanced glycation end 
product (Hosseini & Abdollahi, 2013). Like those for other microvascular 
complications, duration and severity of hyperglycemia are the main risk factor for DN. 
In addition, some individuals may also possess genetic facets that affect their 
predisposition in developing DN (Fowler, 2008). The primary goal of DN treatment is 
to control and prevent the worsening of it symptoms by improving glycemic control. 
Even though there is no specific therapy for DN, many drugs have been prescribed to 
treat its symptoms, for example duloxetine and pregabalin (Boulton, 2007).  
Diabetic nephropathy, a progressive complication in both type 1 and 2 diabetes 
patients, is the leading cause of renal failure in the US (Fowler, 2008). It is defined by 
the presence of proteinuria of more than 500 mg in a 24 h urine collection. This stage 
has been referred to as overt nephropathy, clinical nephropathy, macroalbuminuria or 
proteinuria (Gross et al., 2005). This condition is preceded by microalbuminuria - that is 
the presence of proteinuria of 30-299 mg/ 24 hours. Without any treatment, 
microalbuminuria typically progresses to macroalbuminuria and finally to renal failure 
(Drummond & Mauer, 2002). Pathological changes in kidney structure due to 
nephropathy include glomerulosclerosis, microaneurysm formation, hyalinosis, 
mesangial nodule formation and hyaline arteriosclerosis (Fowler, 2008; Raparia, 
Usman, & Kanwar, 2013). Approximately 15-40% of patients with type 1 DM and 5-
20% of patients with type 2 DM have macroalbuminuria/ diabetic nephropathy. The 
prevalence of diabetic nephrophaty was higher in Asian, African Americans, and Native 
Americans populations than Caucasians (Gross et al., 2005). Like other diabetes 
microvascular complications, poor glycemic control remains as the major initiation and 
progression factors for diabetic nephropathy. Other putative risk factors include 
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glomerular hyperfiltration (Dahlquist, Stattin, & Rudberg, 2001), age of onset, smoking, 
hypertension, obesity and dyslipidemia (Kramer et al., 2005). Initial treatment of 
diabetic nephropathy, as of other diabetes microcascular complications, is prevention 
which is treating its known risk factors, namely hyperglycemia, hypertension, 
dyslipidemia and tobacco use. In addition, treatment with antihypertensive drugs, 
angiotensin-converting enzyme (ACE) inhibitors and angiotensin-II receptor blockers 
(ARBs) have shown to lower the risk of developing nephropathy and cardiovascular 
event in type 2 DM (Gross et al., 2005). 
Macrovascular complications associated with diabetes include cerebrovascular, 
cardiovascular, and peripheral artery diseases. Cerebrovascular disease refers to many 
disorders involving blood vessels of the central nervous system (CNS). These disorders 
result from either inadequate blood flow to the brain (i.e., ischemic stroke) or from 
hemorrhages into the parenchyma or subarachnoid space of the CNS (i.e. cerebral 
hemorrhage) (King, Jones, & Warthen, 2005). Type 2 diabetes is an independent risk 
factor for cerebrovascular complications; diabetic patients are up to 2- 4 times more 
susceptible to a stroke event (Muntean, Mitrea, Mota, & Tudorica, 2012) and have 
poorer long-term prognosis, more severe neurological disability and higher incidence of 
stroke recurrence than non-diabetic patients (Elneihoum, Göransson, Falke, & Janzon, 
1998; Sprafka, Virnig, Shahar, & McGovern, 1994). Hyperglycemia, hyperinsulinemia 
and excess free fatty acid cause deleterious effects on the cerebrovascular endothelial by 
several mechanisms namely oxidative stress, hypercoagulability, inflammation and 
artherosclerosis which lead to the initiation of cerebrovascular disorders (Patel, 2016). 
Sudden confusion, loss of coordination, unilateral weakness, and numbness are warning 
signs of a cerebrovascular event (King et al., 2005). The risk factors that may 
predispose a patient to a stroke include smoking, obesity, hypertension, dyslipidemia, 
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and transient ischemic attacks (Stegmayr & Asplund, 1995). The FDA has approved the 
use of an intravenous tissue plasminogen activator (tPA) for treatment of patients with 
acute ischemic stroke (King et al., 2005). 
Cardiovascular diseases (CVDs) are a group of diseases of the heart and blood 
vessels which include coronary heart disease, myocardial infarction, heart attack, 
angina, stroke and congenital heart disease (WHO, 2007). Generally, individual with 
diabetes have 2 to 4 times greater risk to develop CVD and insulin resistance condition 
further worsen the long term prognosis of the CVDs (Buyken, von Eckardstein, Schulte, 
Cullen, & Assmann, 2007; Cade, 2008). Diabetic patients frequently have several 
traditional risk factors that contribute to CVDs namely lifestyle (tobacco use and diet), 
hypertension and dyslipidemia (Buyken et al., 2007). The combination of 
hyperglycaemia, insulin resistance, chronic inflammation and the aforementioned 
traditional risk factors for CVDs can cause injury to vascular endothelium, 
hypercoagulability, oxidative stress, impaired fibrinolysis, platelet hyperaggregability 
and glucose toxicity that lead to macrovasculopathy and CVDs in diabetic patients 
(Beckman, Creager, & Libby, 2002; Haffner & Steven, 2005). Like other diabetes 
complications, the primary goal of therapy of CVDs is prevention which could be 
achieved via several ways. For type 1 diabetes patients, maintaining good glycemic 
control helps to lower the risk of CVDs as several studies have shown that patients with 
higher degree of hyperglycemia tend to have higher heart rate which is related with 
higher risk of CVDs (Fowler, 2008). Good glycemic control can be achievable using 
insulin and/or any oral antidiabetic drugs (King et al., 2005). In type 2 diabetes patients, 
the risk of CVDs can be lowered by having ideal blood pressure which can be 
accomplished using antihypertensive agents namely ACE inhibitors, ARBs, thiazide 
diuretics and non-dihydropyridine calcium channel blockers (Chobanian, 2003; 
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Lindholm et al., 2002). Another available therapy for CVDs is maintaining blood lipid 
concentration namely LDL, triglycerides and HDL. Numerous studies have reported 
reduced risk of cardiovascular events in diabetic patients who are treated with lipid 
lowering agents such as statins (Bitzur, 2011). 
Peripheral artery disease (PAD) is an atherosclerotic occlusive disease of the 
lower extremity arteries (Kullo et al., 2003). The fundamental symptoms of PAD are 
intermittent claudication during exercise in the affected leg and pain at rest which is 
experienced by patients with critical limb ischemia (Creager & Libby, 2001; Schainfeld, 
2001). These conditions can cause functional disabilities and impairments of the lower 
extremities that eventually lead to amputations (McDermott et al., 2004). The strongest 
risk factor for PAD is diabetes mellitus and smoking (Fowkes et al., 2013). Diabetes 
patients have a threefold to fourfold greater risk of developing PAD, as well as 
accelerates its course, compared to patients without diabetes (Murabito, D’Agostino, 
Silbershatz, & Wilson, 1997). Insulin resistance, hyperglycemia and dyslipidemia 
promote the development and progression of PAD via several mechanisms include 
derangements of the vessel wall through stimulation of endothelial cell dysfunction, 
triggering vascular inflammation and causing abnormalities in muscle cells, blood cells 
and factor affecting homeostasis (Armstrong, Waltenberger, & Rogers, 2014). Other 
risk factors are hypertension, dyslipidemia, sedentary lifestyle, obesity and a history of 
cardiovascular disease (Wattanakit et al., 2005). Treatment of PAD focuses on lowering 
symptoms and hindering further development of PAD. In most cases, lifestyle changes 
including smoking cessation, regular exercise, healthy diet and controlled high blood 
pressure, diabetes and dyslipidemia are sufficient to delay the progression or even 
reverse the signs and symptoms of PAD (King et al., 2005). If needed, medications will 
be given according to the underlying causes of PAD for example statins 
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(antihyperlipidemic drug), ACE inhibitors (antihypertensive drugs), low dose aspirin 
and clopidogrel (antiplatelet drugs) and naftidrofuryl oxalate (Poredos & Jezovnik, 
2015). 
 
1.5  Oral diabetes medications  
Diabetes mellitus is chronic metabolic disorder that requires continuous medical care 
with patient self-management education in order to achieve ideal blood glucose level, to 
avoid acute complications and to lower the risk of long term complications (Shafiee, 
Mohajeri-Tehrani, Pajouhi, & Larijani, 2012). Until the year of 1995, there are only two 
choices of therapy for managing diabetes; insulin for type 1 and type 2 diabetes and 
sulfonylureas for type 2 diabetes. After the year of 1995, there is a drastic change in the 
choice of therapy as number of insulin analogs and oral antidiabetic agents have been 
approved. Currently, eleven classes of oral antidiabetic drugs are available; 
sulfonylureas, meglitinides, thiazolidinediones, biguanides, α-glucosidase inhibitors, 
dipeptidyl peptidase IV inhibitors, glucagon-like peptide-1 receptor agonists, amylin 
agonists, bromocriptine, colesevelam and sodium glucose co-transporter 2 inhibitors 
(John R White, 2014). These drugs are classified according to their mechanism of 
glucose lowering action. Figure 1.2 shows schematic representation of potential new 
drug target areas. Sulfonylureas and meglitinides are known as insulin secretagogues 
due to their effects in triggering insulin release from the pancreatic β-cells. On the other 
hand, biguanides and thiazolidinediones are considered as insulin sensitizers because of 
their abilities to enhance insulin sensitivity of insulin-responsive tissues. American 
Diabetes Association recommends a trial of diet and exercise as the first line therapy for 
the management of type 2 DM (Pan et al., 1997). If the desired level of glycemic control 
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is not attained with diet and exercise within the period of three months, pharmacologic 
therapy should be introduced. 
 
Figure  1.2: Schematic representation of potential new drug target areas. Abbreviations: 
↑, increase; ↓, decrease; GLUT 4, insulin – stimulated GLUT 4; PEPCK, phospoenol 
pyruvate carboxykinase; PI 3 – kinase, phosphatidylinositol 3 – kinase; PKB, protein 
kinase B (Bailey, 2000).  
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1.5.1  Sulfonylureas 
The primary action mechanism of sulfonylureas is to increase insulin release from 
pancreas. It binds to the sulphonylurea receptors on pancreatic β-cells that leads to the 
closure of adenosine triphosphate (ATP)-sensitive potassium channel, thus inhibit the 
efflux of potassium. The inhibition of potassium efflux results in depolarization of β-
cells. Depolarization opens a voltage-gated calcium channel and allows an influx of 
Ca2+ into β-cells. The presence of intracellular Ca2+ caused translocation of insulin 
secretory granules to the cell surfaces. The insulin granules are subsequently released 
via exocytosis process (DiPiro et al., 2011). In addition, two other mechanisms of action 
of sulfonylureas have been suggested, which are reduction of serum glucagon 
concentration and potassium channels closure in extrapancreatic tissue (Katzung, 
Masters, & Trevor, 2004). The major adverse effect of sulfonylureas is hypoglycemia, 
which is more problematic with long-acting formulations, chronic liver disease or renal 
insufficiency. Elderly were the most at risk of hypoglycemia. Weight gain of 
approximately 2% is also observed following the initiation of sulfonylurea therapy. 
 
 
1.5.2  Biguanide 
Metformin, as the only clinically significant biguanide available, is the most widely 
‘insulin sensitizing agent’ prescribed worldwide. It improves blood glucose level by 
increasing insulin-mediated suppression of hepatic glucose production, and by 
enhancing insulin sensitivity of peripheral tissues which optimize the uptake of glucose 
into these insulin – responsive tissues. Several mechanisms of how metformin improves 
insulin sensitivity have been proposed; by enhancing synthesis of glycogen and 
increasing the activity of insulin receptor tyrosine kinase and GLUT 4 (Giannarelli, 
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Aragona, Coppelli, & Del Prato, 2003). Metformin has no direct effect on the viable β-
cells of pancreas, though insulin levels are lowered, corresponding to an increase in 
insulin sensitivity. Several non-glycemic benefits have been reported with the treatment 
of metformin which are decreasing incidence of myocardial infarction, lowering 
cardiovascular risk factors and reducing diabetes-related deaths. The occurrence of 
hypoglycemia with metformin monotherapy is minimal.   
 
1.5.3  α-glucosidase inhibitors 
α-glucosidase inhibitors (AGIs), also known as ‘starch blockers’ are a class of drugs 
that act by delaying the absorption of carbohydrate in the gastrointestinal tract. AGIs 
delay the absorption of carbohydrate by inhibiting several α-glucosidase enzymes (e.g. 
maltase sucrose, isomaltase, and glucoamylase) which are responsible for the 
breakdown of oligosaccharides and dissacharides into monosaccharides. This process 
will result in reduced postprandial glycemic levels, with a modest effect on fasting 
glucose (J. R. White, 2009). Acarbose is the most widely prescribed AGIs. AGIs might 
be a suitable candidate in the treatment of type 2 diabetes mellitus as they specifically 
use for marked postprandial hyperglycemia, a possible independent risk factor for the 
development of cardiovascular complications (Ceriello, 2005). Even though scarce 
cases of hepatic injury were reported, AGIs are expected to cause no hypoglycemic or 
other life-threatening events, even at overdoses (Chiasson et al., 2004). 
 
 
 
 20 
 
1.5.4  Meglitinides 
Meglitinides is a short acting insulin secretagogues drug, which in similar to 
sulfonylureas, lowers blood glucose level by stimulating pancreatic insulin release. The 
insulin release, however, is glucose dependent and becoming less at low blood glucose 
concentration. Hence, the risk of hypoglycemic event and weight gain with meglitinides 
therapy appears to be lesser than with sulfonylureas therapy. The rate of hypoglycemia 
of repaglinide and nateglinide (meglitinides) were recorded to be 3% and 15%, versus 
glipizide and glyburide (sulfonylureas) rates of 19% and 15%, respectively (DiPiro et 
al., 2011). In addition, these agents can be used to enhance insulin secretion during 
meals (when it is needed) in patients who are close to glycemic goals. They should be 
administered up to 30 minutes prior to each meal. 
 
1.5.5  Thiazolidinediones 
Thiazolidinediones, also referred to as TZDs or glitazone act by decreasing insulin 
resistance. They work by binding to the perixosome proliferator-activated receptor 
gamma (PPAR-γ), which located primarily on the adipose and vascular cells. The 
frequency of these receptors in the muscle is very low; hence muscle is not the main 
action site of TZDs. PPAR-γ is a nuclear transcription factor that modulate the 
expression of genes involved in glucose and lipid metabolism, transduction of insulin 
signal and differentiation of adipocytes. In diabetic patients, the major action site of 
TZDs is adipose tissue. These drugs promote the uptake and regulation of glucose, 
modulate the synthesis of lipid hormones, cytokines or other proteins that involved in 
energy regulation and control the apoptosis and differentiation of adipocytes. 
Pioglitazone and rosiglitazone are the two member of this class approved by FDA for 
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the treatment of type 2 DM. They have distinct side chains that produced differences in 
therapeutic action, metabolite profile, metabolism and side effects. Both of these agents 
have been related to fluid retention and must be prescribed with caution in congestive 
heart failure patients.  
 
1.5.6  DPP-4 Inhibitors 
Inhibitors of dipeptidyl peptidase (DPP) 4, also known as gliptins, are a group of oral 
hypoglycemic that block DPP-4, an enzyme that destroys incretin. The primary action 
of DPP-4 inhibitor is to prolong the half-life of endogenous incretin levels, which are 
glucagon-like protein 1 (GLP-1) and glucose-dependent insulinotopic hormone (GIP). 
Incretins help the body to release more insulin when it is required and lower the amount 
of glucose being produced by the liver when it is not needed. Incretins hormones are 
produced throughout the day and the levels go higher at meal times. In healthy person, 
incretins are removed from the body rapidly by the DPP-4. Thus, with the presence of 
DPP-4 inhibitors in diabetic patients, incretins could be retained in the body longer, 
resulting in decreasing glucagon level, which subsequently increasing insulin release, 
slowing gastric emptying and lowering blood glucose levels. The clinical data of DPP-4 
inhibitor indicated there was no incidence of hypoglycemia compared with placebo or 
active-controlled anti-diabetic drugs after long term treatment (Li et al., 2016) and it 
could achieve a long-term effective and safe glycemic control for use as monotherapy or 
in combination with metformin (Liu et al., 2014).  
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1.5.7  Incretin mimetic  
Incretin mimetics are a new category of pharmacological agents. Similar to the DPP-4 
inhibitors discussed above, these agents employed the blood glucose lowering actions of 
the incretin hormone, GLP-1. Some of blood glucose lowering actions by GLP-1 are 
enhancing glucose – linked insulin secretion, inhibiting elevated glucagon secretion, 
and decreasing food absorption by slowing food digestion. However, due to the short 
half –life of native GLP-1 (1 to 2 minutes), the long – term use of this hormone in the 
treatment of chronic conditions, namely type 2 DM is limited. This led to the search for 
GLP-1 analogs which are less or more structurally similar to GLP-1 but are not 
degraded by DPP-4 enzyme and have much slower elimination rates, hence longer half-
life. Exenatide is the first incretin mimetics approved by the US Food and Drug 
Administration in 1995, followed by liraglutide in 2010. Later, a long-acting form (once 
weekly) of exenatide became available for clinical use in 2012. Weight loss is one 
beneficial effect of incretin-based therapy. These agents, however, can cause significant 
adverse effects on gastrointestinal, particularly early in the therapy, with mild to 
moderate nausea becomes the most common observed effect. 
 
1.5.8  Amylin analogue  
Amylin, also known as islet amyloid polypeptide (IAP) is an endogenous 
neuroendocrine hormone which is co-secreted with insulin by the pancreatic β-cells. In 
glycemic regulation, amylin promotes satiety and delays gastric emptying, thereby 
preventing postprandial hyperglycemia spikes. Similar with insulin, patients with type 2 
diabetes secreted less amylin, whereas patients with type 1 have relatively no amylin at 
all. Currently, the only available amylin agonist is pramlintide, approved by the FDA in 
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2005. It is administered subcutaneously via injection. This agent is usually reserved for 
use in type 1 diabetic patients that undergo intensive insulin therapy. The major side 
effect of pramlintide is nausea. 
 
1.5.9  Sodium glucose co-transporter inhibitors 
Studies on SGLTs started with the isolation of phlorizin, a glycoside from the bark of 
apple tree in the 19th century. Phlorizin was recognized as a non selective inhibitor of 
both SGLT 1 and SGLT 2 that are responsible for the reabsorption of glucose in the 
kidneys and small intestine (Chasis, Jolliffe, & Smith, 1933). Further development of 
phlorizin as an antidiabetic agent however, was limited by its poor oral bioavailability, 
lack of specificity and potential malabsorption with SGLT 1 inhibition (Mudaliar, 
Polidori, Zambrowicz, & Henry, 2015). This led to the pursuit of selective SGLT2 
inhibitors with improved properties. The primary mechanism of action of SGLT 2 
inhibitors is reducing plasma glucose concentration by enhancing renal excretion of 
glucose (Kalra, 2014). These drugs inhibit SGLT 2, a low-affinity glucose transporter 
that are expressed primarily in the proximal tubule of kidney and responsible for 
approximately 90% of renal glucose reabsorption. When competitive inhibition of 
SGLT 2 occurred, excess renal glucose is not reabsorbed, thus the glucose is excreted in 
the urine. These lead to a net loss of glucose and reduction in plasma glucose level 
(Poudel, 2013). Three SGLT2 inhibitors (dapagliflozin, canagliflozin, and 
empagliflozin) have been approved for use in the U.S. and Europe (Grempler et al., 
2012). Currently, Japan has also approved luseogliflozin, topogliflozin, and ipragliflozin 
as antidiabetic drugs and several other compounds are in late-stage clinical trials 
(Mudaliar et al., 2015). The most common adverse effects of SGLT 2 inhibitors are 
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correlated to their mechanism of action, including uro-genital tract infections which 
occured due to the elevated glucose in urine. These effects are frequently noticed among 
the female patients and uncircumcised male patients (Sarnoski-Brocavich & Hilas, 
2013). To date, there is no SGLT 1 inhibitor that has been approved by FDA or 
European Medicines Agency (EMA) as an antidiabetic agent. Few selective SGLT 1 
inhibitors for example, GSK-1614235 and KGA-2727 were tested in nonclinical and 
clinical trials involving rat and human studies. The results showed that SGLT 1 
inhibitors block intestinal glucose absorption, lower secretion of GIP, and increase 
GLP-1 and peptide YY secretion (Dobbins et al., 2015). 
 
1.5.10  Bromocriptine 
Bromocriptine is a sympatholytic D2 – dopamine agonist that has been approved for use 
as an antihyperlgycemic drug in 2009. The use of bromocriptine in treating diabetes has 
been recognized, based on its action in modulating the pathways of glucose and energy 
metabolism. These actions aid in resetting an abnormally high hypothalamic drive for 
elevated levels of plasma glucose, triglycerides, and free fatty acid in insulin – resistant 
patients (Shivaprasad & Kalra, 2011). Based on animal and clinical studies, a quick 
release bromocriptine formulation, given within two hours of awakening, showed to 
increase low hypothalamic dopamine levels and block excessive sympathetic tone of 
central nervous system, leading to enhanced suppression of glucose production by liver, 
thus resulting in a reduction in postprandial hyperglycemia. The doses used for diabetes 
therapy are far lower than those used in treating Parkinson’s disease. Apart from nausea, 
this agent is well – tolerated.   
 
